Uncover Key Insights on Edwards Lifesciences

By Emilio Sanchez • Thursday, May 01 15:13 • Permanent Link

Large-cap Health Care company Edwards Lifesciences has moved 0.1% so far today on a volume of 1,392,611, compared to its average of 4,787,322. In contrast, the S&P 500 index moved 1.0%.

Edwards Lifesciences trades -5.83% away from its average analyst target price of $80.28 per share. The 30 analysts following the stock have set target prices ranging from $61.0 to $90.0, and on average have given Edwards Lifesciences a rating of buy.

If you are considering an investment in EW, you'll want to know the following:

Edwards Lifesciences's current price is 47.8% above its Graham number of $51.15, which implies that at its current valuation it does not offer a margin of safety
Edwards Lifesciences has moved -11.3% over the last year, and the S&P 500 logged a change of 10.0%
Based on its trailing earnings per share of 2.38, Edwards Lifesciences has a trailing 12 month Price to Earnings (P/E) ratio of 31.8 while the S&P 500 average is 29.3
EW has a forward P/E ratio of 30.9 based on its forward 12 month price to earnings (EPS) of $2.45 per share
Its Price to Book (P/B) ratio is 4.45 compared to its sector average of 3.19
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Based in Irvine, the company has 15,800 full time employees and a market cap of $44.28 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.